[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370747-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370747-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-impact-of-public-insurance-on-rrso-for-hboc-in-japan-a-nationwide-data-study","The impact of public insurance on RRSO for HBOC in Japan: a nationwide data study","","Risk management for hereditary breast and ovarian cancer (HBOC) in Japan includes risk-reducing surgery covered by public insurance for some patients, while non-cancer clients face high copayments. Using nationwide Japanese Organization of Hereditary Breast and Ovarian Cancer data, the study compares RRSO uptake before and after April 2020 insurance coverage, and defines a special short period aligned to follow-up. Results show significantly higher RRSO rates after coverage, including increased BRCA1 and BRCA2-specific uptake.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-impact-of-public-insurance-on-rrso-for-hboc-in-japan-a-nationwide-data-study/370747/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-impact-of-public-insurance-on-rrso-for-hboc-in-japan-a-nationwide-data-study/370747.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study?","Question",{"text":63,"@type":64},"To evaluate how public insurance coverage starting in April 2020 affected the uptake of risk-reducing salpingo-oophorectomy (RRSO) for HBOC in Japan using nationwide data.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study define the comparison periods?",{"text":68,"@type":64},"The period from March 2006 to March 2020 was defined as pre-coverage (Pre), and April 2020 to August 2021 as post-coverage (Post). April 2018 to March 2020 was designated as special (short-Pre) to align with the post period.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings about RRSO rates after insurance coverage?",{"text":72,"@type":64},"RRSO rates increased significantly in the post-coverage period. The study also found significant increases in RRSO uptake when separating BRCA1 and BRCA2.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370747,1790508344,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/jhg](www.nature.com/jhg)  \nARTICLE OPEN   \nThe impact of public insurance on RRSO for HBOC in Japan: a nationwide data study  \nMegumi Matsumoto1, Hiroki Den2, Shoko Miura3, Ayumi Harada4, Hiroyuki Nomura5, Masami Arai6, Hiraku Kumamaru7, Seigo Nakamura8, Masayuki Sekine9 ✉ and Kiyonori Miura3 ✉  \n© The Author(s) 2025  \n\n|  | In Japan, risk management based on genetic disposition, such as risk-reducing surgery for hereditary breast and ovarian cancer (HBOC), is covered by public insurance only for some cancer patients. However, non-cancer clients are forced to pay a high copayment. In this study, we examined the impact of risk-reducing salpingo-oophorectomy (RRSO), before and after the April 2020 public insurance coverage, using nationwide data from the Japanese Organization of Hereditary Breast and Ovarian Cancer. The period from March 2006 to March 2020 was deﬁned as before insurance coverage (Pre), and the period from April 2020 to August 2021 was deﬁned as after insurance coverage (Post) . In addition, the period from April 2018 to March 2020 was designated as special (short-Pre) to coincide with the post-insurance coverage period. Of the 383 breast cancer patients who underwent genetic testing at Short-Pre, 42 (11.0%) underwent RRSO during that period. Of the 623 breast cancer patients who underwent genetic testing at Post, 142 (22.8%) underwent RRSO during that period. Signiﬁcantly, this comparison shows an increase in RRSO rates in Post. Separating BRCA1 and BRCA2 also signiﬁcantly increased RRSO in Post. This nationwide survey suggests that if RRSO is covered by insurance in Japan, the implementation rate will increase. As the number of cases increases in the future, the impact of insurance coverage will become clearer. If the insurance coverage for RRSO in Japan is determined to be useful, this information can be used |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| to expand coverage for those who have not yet developed the disease. |  |  |\n|  | Journal of Human Genetics (2025) 70:421–426; [https://doi.org/10.1038/s10038-025-01326-0](https://doi.org/10.1038/s10038-025-01326-0) |  |\n|  |  |  |\n\nINTRODUCTION  \nHereditary breast and ovarian cancer (HBOC) is among the most common hereditary tumors and is known to be inherited in an autosomal dominant form, involving the BRCA1 and BRCA2 genes [1, 2] . The percentage of BRCA gene pathological variant carriers in the general Japanese population is reportedly 0.21% [3] . The efﬁcacy of Poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of patients with cancer with known BRCA pathological variants has resulted in the use of the BRCA gene as a companion diagnosis [4–7] . Following the Food and Drug Administration’s approval of PARP inhibitors (Olaparib) for treating ovarian cancer in 2014, the drug was initially covered by public insurance in Japan in April 2018 for recurrent ovarian cancer, followed by the extension of coverage to inoperable or recurrent breast cancer, metastatic prostate cancer, and pancreatic cancer not curativelyresectable [8–10] . In addition, the opportunity for HBOC to be diagnosed is increasing because cancer gene panel testing has also been covered by public insurance since 2019 [11] .  \nRisk-reducing salpingo-oophorectomy (RRSO) for BRCA pathological variant carriers has been recommended by various guidelines [9, 12], because it prevents the development of ovarian  \nand fallopian tube cancers, prolongs overall survival [13–19], and reduces cancer mortality through risk-based health management by identifying genetic disposition. In April 2020, in addition to genetic counseling, surveillance, and risk-reducing surgery, BRCA genetic testing (GT) for diagnosing HBOC was also covered by public insurance for some patients with breast and all patients with ovarian cancers in Japan. Although the results of this GT for canc","cbCait9gEhU8PH9G","https://ap.wps.com/l/cbCait9gEhU8PH9G","pdf",792446,"English","# Introduction\n# Materials and Methods\n## Study registration","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To evaluate how public insurance coverage starting in April 2020 affected the uptake of risk-reducing salpingo-oophorectomy (RRSO) for HBOC in Japan using nationwide data.\"},{\"question\":\"How did the study define the comparison periods?\",\"answer\":\"The period from March 2006 to March 2020 was defined as pre-coverage (Pre), and April 2020 to August 2021 as post-coverage (Post). April 2018 to March 2020 was designated as special (short-Pre) to align with the post period.\"},{\"question\":\"What were the key findings about RRSO rates after insurance coverage?\",\"answer\":\"RRSO rates increased significantly in the post-coverage period. The study also found significant increases in RRSO uptake when separating BRCA1 and BRCA2.\"}]","The impact of public insurance on RRSO for HBOC in Japan: a nationwide data study | PDF",1790190187,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/719c7df9f7b4cd807b121e7d70eed5fa.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eb06478c393db9c1a960659ca225f8e.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5de535cd3f3def15f41b159ef609f878.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b054e9741bc8466227ca77761f1b785.webp",980,1301]